Having personally attended as an observer the NICE committee meeting evaluation of RECELL in Manchester I can report the single biggest issue was the lack of independent economic modelling, that would allow the NHS to recommend the use. BARDA funding has fixed this and a return to many markets with tailored economic data will be very rewarding when they get to it.
Why AVH's sale in US is better than Europe and Asia, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.93 |
Change
-0.040(1.01%) |
Mkt cap ! $219.7M | |||
| Open | High | Low | Value | Volume |
| $3.96 | $3.96 | $3.87 | $433.9K | 111.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 514 | $3.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.93 | 11205 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |
